The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

Recruiting now · Phase 2

Conditions studied: Gastric Cancer

In brief

This is a signle-arm, multi-center, open-lable, phase II study. The objective is to evaluate the effectiveness and safety of tislelizumab + oxaliplatin + capecitabine + PLD in the neoadjuvant treatment of resectable gastric adenocarcinoma.

Key facts

Study ID
NCT05536102
Run by
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
People needed
38
Starts
2022-09-05
Expected to finish
2027-09-30
Last updated by the study team
2023-03-09

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.